Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

Inclusion Criteria: * Relapsed or refractory B-cell ALL or CML in lymphoid blast phase; Philadelphia chromosome must be present at screening (as determined by cytogenetic analysis, fluorescence in situ hybridization \[FISH\], or polymerase chain reaction \[PCR\] \[i.e., BCR-ABL positive\]); Note: patients with CML who have received treatment with tyrosine kinase inhibitors for their CML, and have progressed to lymphoid blast phase are eligible for frontline treatment; Frontline Ph+ ALL or CML-lymphoid blast phase (LBC) Cohort: Patients with newly-diagnosed Ph+ ALL or CML-LBC, who have received no or minimal treatment (minimal treatment is defined as treatment with steroids/hydroxyurea of =\< 2 week duration; vincristine =\< 2 doses; tyrosine kinase inhibitor of =\< 4 week duration; =\< 2 doses of cytarabine) and are \>= 60 years or older are eligible; patients must have bone marrow blasts \> 5% at the time of screening * Expression of CD-22 in \>= 20% blasts * Eastern Cooperative Oncology Group (ECOG) performance status score of \< or = 2 * Serum bilirubin \< or = 2.0 mg/dl * Serum creatinine \< or = 2.0 mg/dl * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \< or = 3 x upper limit of normal (ULN) * Females of childbearing potential must have a negative serum or urine beta human chorionic gonadotropin (beta-hCG) pregnancy test result within 14 days prior to the first dose of study drugs and must agree to use one of the following effective contraception m…